286 related articles for article (PubMed ID: 20850842)
41. Altered Ets transcription factor activity in prostate tumor cells inhibits anchorage-independent growth, survival, and invasiveness.
Foos G; Hauser CA
Oncogene; 2000 Nov; 19(48):5507-16. PubMed ID: 11114728
[TBL] [Abstract][Full Text] [Related]
42. Regulation of Bcl-2 expression by dihydrotestosterone in hormone sensitive LNCaP-FGC prostate cancer cells.
Bruckheimer EM; Spurgers K; Weigel NL; Logothetis C; McDonnell TJ
J Urol; 2003 Apr; 169(4):1553-7. PubMed ID: 12629413
[TBL] [Abstract][Full Text] [Related]
43. Indole-3-carbinol induces a G1 cell cycle arrest and inhibits prostate-specific antigen production in human LNCaP prostate carcinoma cells.
Zhang J; Hsu B A JC; Kinseth B A MA; Bjeldanes LF; Firestone GL
Cancer; 2003 Dec; 98(11):2511-20. PubMed ID: 14635088
[TBL] [Abstract][Full Text] [Related]
44. Aspirin enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in hormone-refractory prostate cancer cells through survivin down-regulation.
Yoo J; Lee YJ
Mol Pharmacol; 2007 Dec; 72(6):1586-92. PubMed ID: 17848598
[TBL] [Abstract][Full Text] [Related]
45. Suppression of LNCaP prostate cancer xenograft tumors by a prostate-specific protein tyrosine phosphatase, prostatic acid phosphatase.
Igawa T; Lin FF; Rao P; Lin MF
Prostate; 2003 Jun; 55(4):247-58. PubMed ID: 12712404
[TBL] [Abstract][Full Text] [Related]
46. Development of prostate-specific antigen promoter-based gene therapy for androgen-independent human prostate cancer.
Gotoh A; Ko SC; Shirakawa T; Cheon J; Kao C; Miyamoto T; Gardner TA; Ho LJ; Cleutjens CB; Trapman J; Graham FL; Chung LW
J Urol; 1998 Jul; 160(1):220-9. PubMed ID: 9628654
[TBL] [Abstract][Full Text] [Related]
47. Expression of prostate specific antigen (PSA) is negatively regulated by p53.
Gurova KV; Roklin OW; Krivokrysenko VI; Chumakov PM; Cohen MB; Feinstein E; Gudkov AV
Oncogene; 2002 Jan; 21(1):153-7. PubMed ID: 11791186
[TBL] [Abstract][Full Text] [Related]
48. Gene profiling and promoter reporter assays: novel tools for comparing the biological effects of botanical extracts on human prostate cancer cells and understanding their mechanisms of action.
Bigler D; Gulding KM; Dann R; Sheabar FZ; Conaway MR; Theodorescu D
Oncogene; 2003 Feb; 22(8):1261-72. PubMed ID: 12606954
[TBL] [Abstract][Full Text] [Related]
49. Digitoxin inhibits the growth of cancer cell lines at concentrations commonly found in cardiac patients.
López-Lázaro M; Pastor N; Azrak SS; Ayuso MJ; Austin CA; Cortés F
J Nat Prod; 2005 Nov; 68(11):1642-5. PubMed ID: 16309315
[TBL] [Abstract][Full Text] [Related]
50. Prostate derived ETS factor (PDEF): a putative tumor metastasis suppressor.
Steffan JJ; Koul HK
Cancer Lett; 2011 Nov; 310(1):109-17. PubMed ID: 21764212
[TBL] [Abstract][Full Text] [Related]
51. Cardiac glycosides may affect prostate specific antigen levels.
Pouliot F; Wu L
J Urol; 2010 Nov; 184(5):1831-2. PubMed ID: 20846675
[No Abstract] [Full Text] [Related]
52. PDEF downregulates stathmin expression in prostate cancer.
Sabherwal Y; Mahajan N; Helseth DL; Gassmann M; Shi H; Zhang M
Int J Oncol; 2012 Jun; 40(6):1889-99. PubMed ID: 22378487
[TBL] [Abstract][Full Text] [Related]
53. Cardiac glycosides display selective efficacy for STK11 mutant lung cancer.
Kim N; Yim HY; He N; Lee CJ; Kim JH; Choi JS; Lee HS; Kim S; Jeong E; Song M; Jeon SM; Kim WY; Mills GB; Cho YY; Yoon S
Sci Rep; 2016 Jul; 6():29721. PubMed ID: 27431571
[TBL] [Abstract][Full Text] [Related]
54. Pharmacodynamic distinctions between ouabain, digoxin and digitoxin.
Runge TM; Stephens JC; Holden P; Havemann DF; Kilgore WM; Dale EM; Dalton RE
Arch Int Pharmacodyn Ther; 1975 Mar; 214(1):31-45. PubMed ID: 1156023
[TBL] [Abstract][Full Text] [Related]
55. Chronic hypertension induced by ouabain but not digoxin in the rat: antihypertensive effect of digoxin and digitoxin.
Manunta P; Hamilton J; Rogowski AC; Hamilton BP; Hamlyn JM
Hypertens Res; 2000 Sep; 23 Suppl():S77-85. PubMed ID: 11016824
[TBL] [Abstract][Full Text] [Related]
56. Differential species sensitivity to the inhibitory effect of cardiac glycosides on 3H-1-noradrenaline accumulation by tissue slices.
Stickney JL
Arch Int Pharmacodyn Ther; 1976 Dec; 224(2):215-29. PubMed ID: 1015919
[TBL] [Abstract][Full Text] [Related]
57. [Influence of cardiac glycosides on the uptake of 5-HT by blood platelets].
Barthel W; Markwardt F
Biochem Pharmacol; 1971 Oct; 20(10):2597-601. PubMed ID: 4255928
[No Abstract] [Full Text] [Related]
58. Inotropic action, myocardial uptake and subcellular distribution of ouabain, digoxin and digitoxin in isolated rat hearts.
Fricke U; Hollborn U; Klaus W
Naunyn Schmiedebergs Arch Pharmacol; 1975; 288(2-3):195-214. PubMed ID: 1161045
[TBL] [Abstract][Full Text] [Related]
59. Why Whip the Starving Horse When There Are Oats for the Starving Myocardium?
Fürstenwerth H
Am J Ther; 2016; 23(5):e1182-7. PubMed ID: 25259953
[TBL] [Abstract][Full Text] [Related]
60. Biochemical and cross-resistance studies with HeLa cell mutants resistant to cardiac glycoside SC4453. Regulation of the resistant form of Na+/K+-ATPase in the mutant cells.
Chopra A; Gupta RS
J Biol Chem; 1986 Feb; 261(5):2034-40. PubMed ID: 3003091
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
